Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(66.7%)
N/A
1(33.3%)
3Total
Phase 3(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04525417Not ApplicableCompleted

Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers

Role: lead

NCT04494581Completed

GriCoVax Study in 4 Maternity Wards in the Ile-de-France Region

Role: lead

NCT02998320Phase 3Completed

Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

Role: lead

NCT01114425Phase 3Completed

Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection

Role: lead

All 4 trials loaded